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Abstract.
Background: Genetic testing of familial Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) is attract-
ing interest thanks to innovative primary prevention clinical trials and increased request for information by at-risk individuals.
However, ethical, social, and psychological implications are paramount and genetic testing must be supported by structured
genetic counseling. In Italy, practice parameters and guidelines for genetic counseling in dementia are not available.
Objective: To develop a nationally harmonized protocol for genetic counseling and testing of familial AD and FTLD.
Method: Activities were carried out in the context of the Italian Dominantly Inherited Alzheimer’s and Frontotemporal
Network (IT-DIAfN) project, a national network of centers of excellence with expertise in managing patients with familial
AD and FTLD. A survey of the literature on genetic counseling protocols and guidelines was conducted. Local protocols
for genetic counseling were surveyed. Differences and commonalities among protocols were identified and discussed among
project partners. Consensus was reached following implicit aggregation methods.
Results: Consensus was reached on a protocol for patients with clinically diagnosed familial AD or FTLD and a distinct
protocol for their at-risk relatives. Genetic counseling should be provided by a multidisciplinary team including a geneticist,
a neurologist/geriatrician, and a psychologist/psychiatrist, according to the following schedule: (i) initial consultation with
tailored information on the genetics of the dementias; (ii) clinical, psychological, and cognitive assessment; if deemed
appropriate (iii) genetic testing following a structured decision tree for gene mutation search; (iv) genetic testing result
disclosure; (v) psychological support follow-up.
Conclusions: This genetic counseling protocol provides Italian centers with a line of shared practice for dealing with the
requests for genetic testing for familial AD and FTLD from patients and at-risk relatives, who may also be eligible participants
for novel prevention clinical trials.
Keywords: Alzheimer’s disease, frontotemporal degeneration, genetic counseling, genetic testing
INTRODUCTION
Alzheimer’s disease (AD) and frontotemporal
lobar degeneration (FTLD) are two of the most com-
mon forms of dementia. Although the majority of
cases are sporadic (i.e., without a family history),
a markedly familial component has been reported
in 60% of early onset (<65 years) AD patients [1]
and in 25–50% of FTLD patients [2, 3]. An autoso-
mal dominant mode of inheritance is found in about
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1–5% of AD and 10–50% of FTLD cases [4, 5]:
specifically, pathogenic AD mutations were identi-
fied in the amyloid precursor protein (APP) [6] and
the presenilin (PSEN1 and PSEN2) genes [7, 8],
while the genes mainly involved in FTLD are the
microtubule associated protein tau (MAPT) [9–11],
the progranulin (GRN) [12, 13], and Chromosome
9 open reading frame 72 (C9orf72) [14, 15]. Since
the majority of GRN pathogenetic mutations cause
protein haploinsufficiency, the dosage of circulating
progranulin has been proposed as a useful tool for a
quick and inexpensive large-scale screening of GRN
mutations carriers [16–19].
Genetic testing for AD and FTLD is changing
rapidly due to the increasing availability of new and
faster technologies for DNA test, and it is attracting
interest from patients and families thanks to inno-
vative primary prevention clinical trials targeting
genetic dementia and to the growing request for
information by at-risk individuals. Two recent inno-
vative clinical trials targeting genetic dementia are
the Dominantly Inherited Alzheimer Network Trial
for AD (DIAN-TU, http://www.clinicaltrials.gov/
show/NCT01760005) and the Presymptomatic
Neurodegeneration Initiative for FTLD (PreNI,
http://www.neurodegenerationresearch.eu/initiatives/
jpnd-alignment-actions/longitudinal-cohorts/call-for
-working-groups/call-results/). Genetic mutation
carriers, both symptomatic and asymptomatic, could
therefore be eligible participants for these novel
clinical trials.
Genetic testing in symptomatic patients is used to
confirm the clinical diagnosis (diagnostic DNA test);
genetic testing in cognitively unimpaired relatives of
patients with a mutation identifies those who will
develop the disease in the future (predictive DNA test)
[20–23]. In at-risk asymptomatic relatives, predic-
tive genetic testing offers the possibility of assessing
their personal risk, thus allowing them to organize
their lives and make informed career or reproductive
choices and decisions [23]. Undergoing predictive
tests may help at-risk individuals to cope emotionally
with their genetic risk by reducing uncertainty about
their status and focusing on planning for the future
[24], as suggested by a seminal study in Huntington’s
disease [25]. As compared to Americans, Italian at-
risk relatives expressed higher intentions to undergo
genetic testing [20].
However, together with these potential advantages,
genetic tests have important ethical, social, legal, and
psychological implications for the patients and the
whole family. In fact, the identification of a genetic
mutation in a patient implicitly defines the risk for
the other family members, with possible implication
for their health and their future. On the other hand,
information on genetic status cannot be sensibly used
for therapeutic purposes, as no approved disease-
modifying treatment is available to date. In healthy
at-risk individuals, there are concerns that a positive
genetic testing may trigger a negative psycholog-
ical response, such as severe depression, anxiety,
helplessness, or even suicidal ideation [26]. From a
social/legal perspective, there may be issues of poten-
tial genetic discrimination, difficulties in finding a
job or service assistance (including insurance impli-
cations), and in creating relationships [21].
Current guidelines for AD and other inherited
dementia recommend that genetic testing should be
offered within a proper genetic counseling procedure
[21]. For asymptomatic at-risk individuals, the pro-
tocol established for Huntington’s disease, recently
revised [27], is recommended.
With the advent of the prevention clinical trials
in dementia, such as DIAN-TU for AD in pre-
symptomatic mutation carriers, disclosure of genetic
status is a pre-condition to participate in a trial in Italy.
Such disclosure cannot be made without effective pre-
and post-genetic testing support [28].
To date, in Italy no practice standards and
consensus-based guidelines are available for genetic
counseling of familial AD or FTLD. The IT-DIAfN
project, a network of Italian centers of excellence with
recognized experience in managing patients with
familial AD and FTLD, aimed at developing a harmo-
nized and structured protocol for genetic testing and
counseling for those families, both for symptomatic
patients and at-risk relatives. As inherited AD and
FTLD are genetically heterogeneous and symptoms
often overlap, we also generated a decision tree to
assist clinicians/researchers in mutations search.
METHODS
This study was conducted as part of the “Italian
Dominantly Inherited Alzheimer’s and Frontotempo-
ral Network (IT-DIAfN)”, a national project funded
by the Italian Ministry of Health (RF-2010-2319722,
Bando Ricerca Finalizzata 2010). It gathers six
centers of excellence in the study of genetic AD
and FTLD: IRCCS Istituto Centro San Giovanni
di Dio Fatebenefratelli of Brescia, IRCCS Fon-
dazione Istituto Neurologico Carlo Besta of Milan,
University of Florence, Centro Regionale di Neuro-
genetica of Lamezia Terme, University of Brescia,
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and Fondazione IRCCS Ca` Granda Ospedale Mag-
giore Policlinico of Milan.
A working group was composed by geneticists,
psychologists, neurologists, and bioethicists, with at
least one representative from each center, with the
collaboration of the Department of Health Sciences,
University of Genova and Division of Medical Genet-
ics, Galliera Hospital, Genova.
As a first step, the group conducted a survey of
genetic counseling protocols approved by the local
ethics committees and in use at each center. In par-
ticular, the group collected information regarding
the professionals involved in the genetic counseling
team, tests used for the assessment, phases, pro-
cedures, timelines, informed consent forms, access
criteria, and specific requests from the local ethics
committees. Moreover, other specific issues were
addressed, such as the informed consent/refusal for
storage of the biological samples in a biobank for
possible future research studies. Literature search and
experience from centers were combined to develop a
decision tree to assist in the search of the mutation,
to be more accurate, and to reduce time and cost.
A literature search was conducted to analyze guide-
lines or recommendations available for other genetic
diseases, such as Huntington’s disease [27, 29, 30], or
in use in other countries. Italian regulations for data
protection were considered (The Italian Data Pro-
tection Authority, General Authorisation No. 8/2014
for the Processing of Genetic Data, doc. web No.
3632835).
In February-March 2013 the working group partic-
ipated in the first meetings (one in-person and one a
remoto, via teleconferences) aimed at identifying and
discussing the surveyed differences and commonal-
ities among protocols. The first draft was discussed
during an in-person meeting in July 2013 and circu-
lated to the working group in the ensuing months. All
comments and feedbacks were periodically summa-
rized and collated by the Project Coordinator, who
was in charge of moderating the discussion via elec-
tronic communication and of reconciling the different
viewpoints to reach a consensus. The final consen-
sus was reached in October 2014 following implicit
aggregation methods [31]: the group experts in each
field guided the decision-making process and the final
consensus was defined by majority position. Further
comments from SINdem (Italian Society for the study
of Dementias) were also taken into account.
The harmonized protocol for genetic counseling
was approved in February 2015 by the Ethics Com-
mittee of the Coordinating Centre of the IT-DIAfN
project (IRCCS Istituto Centro San Giovanni di Dio
Fatebenefratelli of Brescia).
RESULTS
Survey for Local Protocols
The results of the survey are reported in Table 1.
In all centers, a multidisciplinary team, including
a geneticist, a neurologist, and a psychologist or a
psychiatrist, provided genetic counseling. The sched-
ule of the consultation and the procedures varied
among centers. Three centers divided the procedure
into three consultations: the first was an informational
meeting, where the family history was collected and
the subjects underwent a neurological and a psycho-
logical examination; the second was the blood sample
collection, while the third was the disclosure of the
genetic test results. The other three centers divided the
pre-test phase into two visits: one informational and
one for the assessment of the patient. The timetable
for the visits and for the supportive follow-up var-
ied from center to center. Moreover, some centers
considered the follow-up as non-mandatory or they
offered it only in case of positivity of the test. Differ-
ent tests were used to assess different domains locally
(Table 1). Only two centers had a specific protocol
for symptomatic subjects (diagnostic test), while all
centers had a protocol for at-risk relatives.
Harmonized Protocol for Genetic Counseling
Target population
Genetic counseling can be requested (and even-
tually stopped or suspended at any stage) by (i)
symptomatic patients with a positive family history
suggestive of an autosomal dominant genetic cause
for AD and FTLD and (ii) relatives of patients with
proven genetic AD or FTLD. Each subject has to be
≥18 years old. A positive family history is defined
within the group based on the presence of one of the
following criteria: i) at least three affected first-degree
relatives in two generations, irrespectively of the age
at onset (AAO); ii) at least two affected first-degree
relatives in two generations, with at least one with
onset at≤65 years; or iii) one affected family member
with onset at ≤60 years or with a suggestive clinical
phenotype (e.g. dementia with atypical presentation
[32], recurring presence in other relatives, peculiar
geographic origin).
Cognitively unimpaired at-risk relatives enter the
counseling and are eligible to undergo the genetic
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testing only after the proven presence of the mutation
in a first-degree symptomatic relative.
Two specific genetic counseling protocols were
defined: one for symptomatic patients (Section Pro-
tocol for symptomatic subjects) and one for at-risk
relatives, with a more relaxed and prolonged schedule
(Section Protocol for at-risk subjects).
Genetic counseling team
Genetic counseling is provided by a multidis-
ciplinary team of health professionals who work
together to provide an individual or a family with
current information and supportive counseling about
genetic testing. Genetic counseling is structured and
guided by a geneticist and by a specialized medical
doctor with specific competences in neurodegenera-
tive diseases. The geneticist, who had education in
genetic counseling, is a specialist in medical genet-
ics with expertise in neurodegenerative diseases.
The specialized medical doctor (neurologist, geri-
atrician, and/or psychiatrist) is the clinical contact
person for the patient: this role can be also played
by the geneticist, but only if he/she is a medical doc-
tor with a consolidated clinical background for the
aforementioned diseases. Beside the geneticist and
the specialized medical doctor, the multidisciplinary
team is composed by other professionals (i.e., a psy-
chologist and/or a psychiatrist), who have expertise in
counseling, and have skills at providing ongoing sup-
port to individuals with possible socio-psychological
consequences associated with the risk of being a
mutation carrier.
Evaluation tests
A common battery of clinical, psychological,
and cognitive tests was defined for symptomatic
patients and their at-risk relatives. Specifically, the
battery includes the Mini-Mental State Examination
(MMSE) [33] and the Clinical Dementia Rating Scale
(CDR) [34], the Questionnaire on the Health Status-
12 (SF-12) [35] and the World Health Organization
Quality of Life (WHOQOL) [36], for the assessment
of quality of life and health status; the State Trait Anx-
iety Inventory (STAI-Y) [37], the Beck Depression
Inventory (BDI) [38], and the Hamilton Rating Scale
for Depression (HRSD) [39], for anxiety and depres-
sion measurement; the Brief COPE (BC) [40], the
Resilience Scale for Adult (RSA) [41], and the Health
Locus of Control (HLC) [42, 43], for the evaluation of
the coping style and the locus of controls. Moreover,
a depth evaluation of the risk of suicide is recom-
mended, if the subject showed suicidal thoughts or
attitudes in the past or at present (item 9 of BDI and/or
item 3 of HRSD). One suggested scale is the Beck
Hopelessness Scale [44, 45]. In addition to these tests,
the at-risk relatives are also assessed with the Big
Five Questionnaire (BFQ) for personality assessment
[46, 47].
The subject is assessed at a pre-test phase, to inves-
tigate his/her ability to cope with the test result.
Except for the MMSE, the CDR, and the BFQ, the
assessment with the other tests is repeated post-test
at different time-points, to monitor the psychological
status of the subject, as specified later in the text and
in Fig. 1A-B.
Based on the profile of the subject, the multidisci-
plinary team can suggest postponement of the genetic
test. The team continues to follow and support the
individual as long as it is deemed necessary by the
team or requested by the subject.
Protocol for symptomatic subjects
The genetic testing for symptomatic subjects has a
diagnostic purpose, i.e., to identify the genetic cause
of the disease and confirm the diagnosis of AD or
FTLD. The procedures are illustrated in Fig. 1A
and include: at least one pre-test consultation, one
meeting for blood withdrawal for the genetic test-
ing, a post-test consultation, where the genetic status
is disclosed (for those who wish to know) and then
three follow-ups. The number of the consultations can
be increased and the timespan relaxed, if required
by the patients of if considered appropriate by the
team. Genetic counseling for symptomatic patients
should be performed in the presence of the care-
giver according to patient’s will, and the individual’s
legal guardian if appointed for the individual patient,
to help the patient in the decision-making process,
specifically to help in understanding and appreciat-
ing the purpose and possible results of the genetic test
and in expressing a choice [21, 48].
First consultation: pre-test. During the first infor-
mational visit, the whole multidisciplinary team
provides general information regarding the familial
forms of dementia and details about genetic counsel-
ing (i.e., timespan, team roles, aims, and procedures),
the reliability of the test, and the interpretation of the
results. The team should explain medical and genetic
terms and avoid technical jargon. The implications of
both positive and negative test result are discussed, as
well as if and how these results will be communicated
to other family members. Patients and their fami-
lies should understand that multiple possible results
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may be revealed: a causative mutation in one of the
genes, no mutation in any of the genes, a variant of
unknown significance, or even mutations or variants
in more than one genes. Supportive information is
given regarding the diagnosis and risk for the genetic
disease in the family and its clinical, psychologi-
cal, sociological, and ethical implications, together
with the impact on the family members. The spe-
cific implications, prospective benefits, and risks of
undergoing genetic testing are discussed. The aim is
to provide as much clear information as possible, and
discuss any question or doubt, to allow subjects to
take an autonomous and informed decision whether
they are willing to undergo genetic counseling and
testing and to know their genetic status. The team
avoids influencing the decision of the individual and
the family, and aims at facilitating their autonomous
decision-making.
If agreed, the subject, and/or his/her legal guardian
on his/her behalf if appropriated, signs the informed
consent form for genetic counseling. The caregiver,
if present according to patient’s wishes, can also
sign the informed consent to express agreement [48].
The family health history is collected to construct
the family pedigree and, where possible, a complete
family history should be collected using a structured
questionnaire. Personal clinical phenotype and fam-
ily history will be used to guide the algorithm for
mutation search (see “Flowchart for genetic testing”)
and to evaluate whether the genetic test is appropriate
(as a guide: [49, 50]).
Finally, if not too severely impaired, the subject
is assessed using the test described in “Evaluation
tests”.
After the consultation, the team provides the
patient with a written summary or brochure with
all the general information discussed in person, to
allow their elaboration and comprehension. In case of
doubts, a second informational visit can be scheduled.
Second consultation: blood sample collection. At the
beginning of the second consultation, the whole team
evaluates whether all the information provided dur-
ing the first visit was fully understood, and it clarifies
any remaining doubts or new questions that may arise.
The results of the assessment (if done) are discussed.
If the patient wishes to proceed with the test, the sub-
ject, and/or his/her legal guardian on his/her behalf if
appropriated, signs the informed consent for genetic
testing and blood sample is collected. The caregiver,
if present according to patient’s wishes, can also sign
the informed consent to express agreement. At this
stage, the patient can decide whether his/her sample
can be stored in a biobank for possible future research
studies on genetic forms of dementia or destroyed
after the completion of the analyses.
The team informs the patient about the timespan for
the completion of molecular genetic analysis (around
two months).
Third consultation: post-test. Within two months
from the blood sample collection, the results are
made available. If the patient still wishes to know, the
genetic test results are disclosed and discussed with
the patient, and a written report is given. The whole
team should assess the individual’s understanding
of his/her situation and adapt the language to the
patient in order to clearly explain the meaning and
the implications of a positive, negative, or unclear test
result.
The team should support and assist the patient and
the family in expressing their emotional reactions to
their genetic status. Before leaving the visit, the pres-
ence of psychological distress should be informally
assessed.
Follow-up. After the disclosure of the results, the
team offers ongoing support and information. Three
different time points for the follow-up were defined:
after 1, 6, and 12 months from the disclosure. The
team collects information about any possible change
that may have occurred in the family and in his/her
everyday life. The patient is qualitatively assessed
about his/her psychological conditions, and the tests
described in “Evaluation tests” are administered,
whenever possible.
Protocol for at-risk subjects
The predictive test in genetic counseling aims at
confirming whether the genetic mutation identified
in the family has been inherited by the at-risk rela-
tive, at a stage where the individual does not present
any symptom. This protocol leads to many more eth-
ical and psychosocial issues than the diagnostic test
in symptomatic subjects, because the potential iden-
tification of being a carrier of an autosomal dominant
mutation almost certainly predicts the future develop-
ment of the disease in an individual that is currently
healthy. Undergoing a predictive test is a highly per-
sonal decision that demands extensive counseling.
The procedures are illustrated in Fig. 1B and
detailed below. The schedule mainly differs from the
diagnostic test in prescribing at least two pre-test con-
sultations before the genetic testing, and in having a
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phone call one week after the disclosure of the genetic
status.
First consultation: pre-test. As for the symptomatic
patients, the first consultation is an informational and
supporting visit, when the whole team covers specific
issues of the familial forms of dementia, genetic coun-
seling and testing, and the implications of the results
(for further details see “First consultation: pre-test” of
“Protocol for symptomatic subjects”). The presence
of a support person is encouraged.
If agreed, the subject signs the informed consent
form for genetic counseling. Then, there is an evalu-
ation of the personal and familial medical history.
After the consultation, the team provides the sub-
ject with a written summary or brochure with all
the general information discussed in person, to allow
their elaboration and comprehension.
Second consultation: pre-test. After one month from
the first visit, the second one is scheduled, to fur-
ther discuss the motivation for the predictive test and
clarify any doubts which may have arisen.
The subject is assessed using the tests described in
“Evaluation tests”.
Third consultation: blood sample collection. The
procedures are the same as for the symptomatic pro-
tocol (see “Follow-up” of “Protocol for symptomatic
subjects”).
Fourth consultation: post-test. The procedures are
the same as for the symptomatic protocol (see “Third
consultation: post-test”).
Follow-up. One week after the disclosure of the
results, the team (specifically the psychologist and/or
psychiatrist), contacts the subject by phone and offers
ongoing support and information. The other follow-
up visits are the same as for the symptomatic protocol
(see “Follow-up” of “Protocol for symptomatic sub-
jects”).
Flowchart for genetic testing
A decision tree was developed to assist in the
search of the mutation in symptomatic patients
(Fig. 2).
If the patient has recently undergone a lumbar
puncture and A and tau levels in the cerebrospinal
fluid (CSF) have been analyzed, this measure guides
the genetic screening. If the CSF tau and A42 lev-
els are abnormal (i.e., tau/A42 >0.52) [51], genetic
Fig. 2. Genetic testing flowchart. Step-by-step algorithm to assist in the search of genetic mutations, for cases with abnormal A and tau
levels in the cerebrospinal fluid (CSF) (left panel) and with normal CSF values or data not available (right panel).
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mutations linked to AD are searched as first. To deter-
mine which gene should be sequenced first (i.e., APP,
PSEN1, or PSEN2), the patient’s AAO is consid-
ered: if the patient has an early AAO (≤65 years),
APP gene (exons 16-17) is sequenced; if negative:
all PSEN1 exons and flanking regions; if negative:
all PSEN2 exons and flanking regions. Instead, if the
patient has a late AAO, PSEN2 gene is the first choice
for sequencing, and then APP and PSEN1. If all AD
genes are mutation-negative, but there is a strong evi-
dence for an autosomal dominant pattern, then genes
linked to FTLD are screened. Plasma progranulin
dosage forGRN null mutation screening has the prior-
ity: if the level is <61.55 ng/ml [19], the presence of
the common Italian p.L271fs (exon8:c.811 814del,
ref sequence NM 002087) mutation is assessed [52];
if no mutation is found, all other exons are sequenced.
Conversely, if the progranulin level is not suggestive
for the presence of null mutations (i.e., >61.55 ng/ml),
the clinical phenotype is taken into account. C9orf72
genetic screening should have the priority in patients
with FTLD and motor neuron disease (FTD–MND),
behavioral variant frontotemporal dementia (bvFTD)
with psychosis, or FTLD with cerebellar features,
while MAPT gene (exons 1, 9–13, as first) should be
the first choice in patients with bvFTD and seman-
tic dementia, progressive supranuclear palsy (PSP),
corticobasal syndrome (CBS), or an early AAO (<60
years). When both C9orf72 and MAPT resulted neg-
ative, then GRN should be tested, given possible false
negative in progranulin plasma screening.
When CSF tau and A levels are normal or not
available, the algorithm is based on the progranulin
dosage, as described previously. When the patient’s
level of progranulin is normal, the clinical pheno-
type is taken into account for guiding the analysis. If
the clinical phenotype is FTD-like, then the priority
between C9orf72 and MAPT is defined as previously
described. If the clinical phenotype is consistent with
AD, then, according to the AAO, APP, PSEN1, and
PSEN2 are screened as described previously. When
no mutation is found, the other branch in the diagram
is followed (Fig. 2).
Lastly, if the DNA analysis is done in an at-risk
subject, only the mutation found in the symptomatic
relative is searched for.
DISCUSSION
Genetic testing has ethical, social, legal, and psy-
chological implications for patients and their family:
when handled by an experienced and qualified multi-
disciplinary team following structured criteria, these
issues can be faced serenely and confidently by fam-
ilies. Here, we present a standard and structured
protocol for genetic testing and counseling for symp-
tomatic and at-risk individuals belonging to families
with suspected forms of autosomal dominant AD or
FTLD. This protocol is not designed for genetic coun-
seling of people who carry susceptibility genetic risk
for AD, such as the apolipoprotein E 4 allele, as
this is only a risk factor for dementia and no defini-
tive prediction can be made about dementia in these
subjects. Moreover, based on the current knowledge,
we would not recommend genetic counseling to all
sporadic FTD cases as the likelihood of finding a
mutation in cases with a negative family history is
presumably low [49] and would thus unnecessarily
increase burden to patients and their families. The IT-
DIAfN protocol provides guidance on the schedule,
the procedures, the tests, and the professional figures
involved in genetic counseling, with the aim to sup-
port and take responsible care of these families. The
tests for clinical, cognitive, and personality assess-
ment were accurately chosen to obtain a concise but
accurate profile of the individual, helping in personal-
izing and adapting the support within the counseling
to his/her possible reactions.
We have taken into account the guidelines for the
genetic testing of Huntington’s disease [27, 29, 30],
which is considered the gold standard for genetic test-
ing for adult onset diseases. As recommend by these
guidelines, we used a multidisciplinary approach to
facilitate the subject’s autonomous decision making:
the geneticist as the expert in genetic counseling
for AD and FTLD, the specialized medical doctor
as the clinical contact person of the patients; and
the psychologist/psychiatrist as the contact person
for counseling, psychological appraisal, and support.
The schedule and timespan of the visits are similar to
those defined for Huntington’s disease: several ses-
sions and phases (pre-, post-testing, and follow-ups)
are crucial to allow free choice, without rushing into
genetic testing before all the necessary explanations
and information are given. Other recommendations
prescribed in the Huntington’s disease guidelines
were adopted here: i) disclosure of the genetic status
is provided both orally and through a written report;
ii) availability of the test only to individuals who have
come of age; iii) possibility of storing the biological
samples in a biobank for research studies after signing
the informed consent.
As described in other existent counseling proto-
cols for AD and FTLD [21, 22], we recommended
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that i) the legal guardian of the symptomatic patient
is present during the counseling to help her/him in
understanding its purpose and possible results of the
genetic test and in expressing a choice, and that ii) a
symptomatic family member should be tested before
an at-risk individual.
The guidelines for genetic counseling for AD
defined by the American College of Medical Genet-
ics and the National Society of Genetic Counselors
[21] specified that genetic counseling could be done
in-person or through videoconferences. The Hunting-
ton’s disease guidelines clearly stated that the results
of the test should be revealed in-person, and not by
phone or mail [27, 30], while psychosocial support
should be available close to the person’s commu-
nity, by phone or telemedicine where necessary. A
few pilot projects demonstrated that telemedicine
can be used to offer medical genetics service on
a remote basis [53]. Preliminary evidence suggests
that genetic counseling can be effectively delivered
in underserved areas, also in late-onset genetic dis-
orders such as familial cancer [54]. The advent of
telegenetics could allow the implementation of this
genetic counseling protocol in clinical research cen-
ters without lowering the clinical standard; it may also
facilitate the enrolment in clinical trials of individuals
who could not access to tertiary care genetics centers.
Nevertheless, it is recommended that the psycholo-
gist/psychiatrist should be always present in person
during the visits.
We developed two specific paths, one for symp-
tomatic patients and one for asymptomatic at-risk
subjects, being aware of the difference of the two
scenarios. In fact, in symptomatic subjects, genetic
testing is aimed at confirming the clinical diagno-
sis and the genetic cause of the disease. A positive
result can provoke hopelessness and sense of guilty
for the possibility of transmission of the mutation
to the offspring. In the case of asymptomatic sub-
jects, psychological, social, and ethical issues are
even more critical, especially in the absence of pre-
vention or treatment options: a correct and careful
counseling will offer them the option of knowing their
condition, cope positively with their future and even-
tually they might be offered the possibility to enter a
novel prevention clinical trial. It must be underlined
that a negative result has different meanings accord-
ing to the two different scenarios: in a symptomatic
subject, this could not exclude definitely that the dis-
ease has a genetic cause (thus it is sporadic), because
an unknown/new mutation could be present but not
yet been discovered; in an at-risk relative, a negative
result confirms almost with absolute certainty that
he/she has not inherited the causative mutation found
in the affected relative and thus he/she has the same
risk of the general population to develop the disease
in the future.
Considering the results reported in Binetti et al.
[20], Italian families with familial dementia showed
poor knowledge of the disease and poor awareness of
personal risk of developing dementia during lifetime.
This means that the first consultation should address
these aspects in details, guiding families to a free and
informed choice.
We developed a step-by-step algorithm for guiding
genetic screening on the basis of biomarker results
and clinical data, to reduce time and cost of the lab-
oratory analysis. Specifically, the decision tree was
defined according to (i) the observed frequency of
genes in specific clinical phenotypes in the litera-
ture [49, 55–58], and specifically in Italian clinical
series [52, 59–65], (ii) the direct experience of the
Italian centers, and (iii) practical considerations, e.g.,
the high speed and low cost of a given screening
procedure (i.e., plasma progranulin dosage). In the
future, other biomarkers can be taken into account
and implemented within the flowchart, such as the
amyloid PET.
The research protocol reported herein reflects the
current practice of Italian centers taking part to the
IT-DIAfN initiative. Should important innovations
be introduced in the clinical practice as well as in
laboratory analyses, the protocol will be amended.
Following the wide availability of next generation
sequencing (NGS) panels for the molecular genet-
ics analysis, the decision tree is subject to changes
accordingly. NGS is not currently applied in all cen-
ters participating into the IT-DIAfN framework, but
appears as the upcoming technology for the muta-
tion analysis in heterogeneous genetic disorders such
as AD and FTLD. To date, the NGS approach pro-
vides the simultaneous analysis of a panel of 17 genes
(PRNP, PSEN1, PSEN2, APP, GRN, MAPT, TREM2,
CHMP2B, CSF1R, FUS, ITM2B, NOTCH3, SER-
PINI1, TARDBP, TYROBP, VCP, SQSTM1). Other
experimental panels of additional genes and SNP
polymorphisms are currently under development
within the IT-DIAfN group. The mutation search
should be completed with two PCR analyses of the
C9orf72 hexanucleotide repeat expansion and the
octapeptide repeat region of PRNP [66].
This protocol, developed by experts in the field,
provides Italian centers with a line of shared practice
for offering genetic counseling to eligible individu-
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als who may benefit from genetic testing for familial
AD and FTLD, and recruit them through a procedure
which is compliant with International recommenda-
tions and good practices.
Future steps will be the validation of the harmo-
nized protocol of genetic counseling. This will be
performed in two steps: i) after approval by local
ethics committees, the protocol will be implemented
in all centers participating into the IT-DIAfN project;
ii) data from each center will be collected and the
results from the pilot stage will be critically reviewed
by the working group who developed the protocol.
The genetic counseling protocol will also be dissem-
inated through medical societies and proposals for
amendments will be acknowledged.
We are aware that the entire procedure, includ-
ing counseling, repeated assessments, and testing,
is highly demanding, especially in terms of human
resources. The procedure is expected to be accom-
plished within a research environment by a multidis-
ciplinary team in centers with specific expertise—
as such it was not designed to be applied in routine
clinical practice in its current version. In the light of
the suggestion raised during the validation phase, an
optimized protocol could be eventually transferred to
clinics, provided that evidence of clinical utility has
been produced and a health technology assessment
has supported its implementation in clinical practice.
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